Literature DB >> 19359343

Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years.

Sharon A Chambers1, Elizabeth Allen, Anisur Rahman, David Isenberg.   

Abstract

OBJECTIVE: To study damage accrual and mortality in British patients with SLE under long-term follow-up for >10 years.
METHODS: We analysed the clinical records of 232 patients with SLE who had at least 10 years of consistent follow-up at University College London Hospital (UCLH). We noted their SLICC/ACR Damage Index (SDI) scores and category of damage at 1 year post-diagnosis of SLE and every 5 years thereafter. For patients who had died, we determined the year and cause of death.
RESULTS: Ninety per cent of patients had no damage at 1 year post-diagnosis of SLE; however by year 10, 50% had accrued some damage. Damage accrual was mostly in the neuropsychiatric, renal and musculoskeletal categories. An increase in damage score was associated with a higher risk of death overall. Forty-four patients died during the period of follow-up. Sepsis, cancer and organ failure (cardiac, renal and liver) were the main causes of death in this group of patients.
CONCLUSIONS: Damage accrual is associated with an increased risk of mortality. Infections remain an important cause of death in patients with SLE.

Entities:  

Mesh:

Year:  2009        PMID: 19359343     DOI: 10.1093/rheumatology/kep062

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  60 in total

1.  Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus.

Authors:  Aimee O Hersh; Laura Trupin; Jinoos Yazdany; Peter Panopalis; Laura Julian; Patricia Katz; Lindsey A Criswell; Edward Yelin
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-08       Impact factor: 4.794

2.  Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?

Authors:  Rina Mina; Hermine I Brunner
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

3.  [Early lupus erythematosus].

Authors:  R Fischer-Betz; M Schneider
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

Review 4.  Prevalence and burden of pediatric-onset systemic lupus erythematosus.

Authors:  Sylvia Kamphuis; Earl D Silverman
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

5.  Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis.

Authors:  Stephen D Marks; Vanita Shah; Clarissa Pilkington; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2010-08-05       Impact factor: 3.714

6.  Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus.

Authors:  Amy H Kao; Christine A McBurney; Abdus Sattar; Apinya Lertratanakul; Nicole L Wilson; Sarah Rutman; Barbara Paul; Jeannine S Navratil; Andrea Scioscia; Joseph M Ahearn; Susan Manzi
Journal:  Transl Stroke Res       Date:  2013-10-27       Impact factor: 6.829

Review 7.  Update on Antiphospholipid Syndrome: Ten Topics in 2017.

Authors:  Ilaria Cavazzana; Laura Andreoli; Maarteen Limper; Franco Franceschini; Angela Tincani
Journal:  Curr Rheumatol Rep       Date:  2018-03-15       Impact factor: 4.592

Review 8.  Global trends, potential mechanisms and early detection of organ damage in SLE.

Authors:  Anselm Mak; David A Isenberg; Chak-Sing Lau
Journal:  Nat Rev Rheumatol       Date:  2012-12-11       Impact factor: 20.543

9.  Organ damage in high-risk patients with systemic and incomplete lupus syndromes.

Authors:  Nancy J Olsen; Maha Yousif; Azza Mutwally; Melinda Cory; Nada Elmagboul; David R Karp
Journal:  Rheumatol Int       Date:  2013-05-30       Impact factor: 2.631

Review 10.  Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Colin Thorbinson; Louise Oni; Eve Smith; Angela Midgley; Michael W Beresford
Journal:  Paediatr Drugs       Date:  2016-06       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.